Skip to main content
ARVN
NASDAQ Life Sciences

Arvinas Posts $0.82 Q3 Loss as Revenue Collapses to $0.5M; Cash Runway to 2H 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.06
Mkt Cap
$491.704M
52W Low
$6.74
52W High
$14.51
52W Position info
4.7% above low
Off High info
51% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

ARVN is trading near its 52-week low of $6.74 (4.7% above the low).

Summary

Arvinas reported a $53.9M third-quarter loss ($0.82 per share) on just $0.5M of revenue after vepdegestrant collaboration revenue stopped recurring, but reaffirmed $558.9M in cash funds operations into the second half of 2028. The next hard catalyst is initial ARV-393 Phase 1 data in Q4 2026.


Key Events · Earnings and Guidance · ARVN

  • Q3 Loss of $0.82 Per Share

    GAAP net loss was $53.9M, or $0.82 per share, versus a $35.1M loss ($0.48) in Q3 2025.

  • Revenue Falls to $0.5M

    Revenue dropped from $41.9M a year ago to $0.5M, consisting only of Rigel royalty revenue, after all remaining Pfizer vepdegestrant deferred revenue was recognized in Q2 2026.

  • Cash Runway Into 2H 2028

    Cash, equivalents, restricted cash and marketable securities totaled $558.9M at September 30, 2026, down $126.5M from $685.4M at December 31, 2025, with $123.0M used in operations.

  • Expenses Cut Sharply

    R&D fell to $46.9M from $64.7M and G&A to $12.6M from $21.0M year over year, with vepdegestrant program spend down $14.2M.


Analysis · ARVN · Life Sciences

The quarter swung back to a $53.9M net loss from a $169.4M profit in Q2, and revenue essentially vanished — $0.5M versus $41.9M a year ago — because the vepdegestrant collaboration revenue with Pfizer was fully recognized in Q2 when the asset was out-licensed to Rigel. More important than the loss is the balance sheet: $558.9M of cash and securities funds operations into the second half of 2028, so there is no near-term financing need even with the stock near its 52-week low. The value case now rests entirely on clinical readouts, starting with initial ARV-393 Phase 1 monotherapy data in Q4 2026, then ARV-027 healthy-volunteer data in 1H 2027 and ARV-6723 initial data in 2H 2027.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARVN was trading at $7.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $491.7M. The 52-week trading range was $6.74 to $14.51. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARVN - Latest Insights

ARVN
Nov 03, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.09
Real-time Price: $6.77 info
Change: -$0.325 (-5%) info
Market Cap: $438.095M info
ARVN
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.77 info
Change: -$0.755 (-10%) info
Market Cap: $438.095M info
ARVN
Oct 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.77 info
Change: -$0.755 (-10%) info
Market Cap: $438.095M info
ARVN
Sep 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.60
Real-time Price: $6.77 info
Change: -$0.835 (-11%) info
Market Cap: $438.095M info
ARVN
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $9.00
Real-time Price: $6.77 info
Change: -$2.24 (-25%) info
Market Cap: $438.095M info